Publicaciones en las que colabora con Luis Ángel León Mateos (8)

2016

  1. Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study

    BMC Cancer, Vol. 16, Núm. 1

2015

  1. Side effects of targeted therapy

    Springer New York, pp. 377-416

2014

  1. Sorafenib in renal cell carcinoma: Decision algorithm

    Cancer and Chemotherapy Reviews, Vol. 9, Núm. 2, pp. 61-64

2013

  1. Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor

    Clinical and Translational Oncology, Vol. 15, Núm. 6, pp. 425-433

  2. Erratum: Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor (Clinical and Translational Oncology DOI: 10.1007/s12094-012-0985-x)

    Clinical and Translational Oncology

2011

  1. Expression of notch1 to -4 and their ligands in renal cell carcinoma: A tissue microarray study

    Cancer Genomics and Proteomics, Vol. 8, Núm. 2, pp. 93-101

  2. Molecular basis of hypertension side effects induced by sunitinib

    Anti-Cancer Drugs, Vol. 22, Núm. 1, pp. 1-8

2007

  1. Guía de práctica clínica: cancro de pulmón e mesotelioma

    Conselleria de Sanidade